Paratek Pharma buy Quitte
Summary
This prediction ended on 10.04.17 with a price of €20.43. The BUY prediction by Quitte for Paratek Pharma saw massive gains of 43.35%. Quitte has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Paratek Pharma | - | - | - | - |
iShares Core DAX® | -1.189% | -3.063% | 10.586% | 15.272% |
iShares Nasdaq 100 | 3.663% | 8.732% | 34.914% | 58.325% |
iShares Nikkei 225® | -1.422% | -0.414% | 3.883% | 4.190% |
iShares S&P 500 | 2.182% | 4.907% | 28.279% | 51.241% |
Comments by Quitte for this prediction
In the thread Paratek Pharma diskutieren
sieht doch gut aus
Stand 2. März 2017
BOSTON (AP) _ Paratek Pharmaceuticals Inc. (PRTK) on Thursday reported a loss of $26.5 million in its fourth quarter.
The Boston-based company said it had a loss of $1.16 per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.29 per share.
The pharmaceutical company posted revenue of $29,000 in the period.
For the year, the company reported that its loss widened to $111.6 million, or $5.51 per share. Revenue was reported as $29,000.
Paratek shares have decreased roughly 2 percent since the beginning of the year. The stock has dropped nearly 3 percent in the last 12 months.